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Background and Aims 
Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy 
and represents the second cause of cancer related death worldwide, characterized by high 
recurrence rates and poor survival, even when detected and treated at its early stages. 
Mitochondrial mutations have been known to play a role in carcinogenesis, but to 
date, few studies correctly prioritize and interpret the variants discovered. Thus, we aimed 
to identify and analyze the occurrence and clinical impact of mtDNA mutations in the HCC 
dataset from The Cancer Genome Atlas (TCGA) consortium - National Cancer Institute.  
 
Method 
Whole exome sequencing fastq files from 377 TCGA-HCC patients were downloaded 
from the TCGA database. Paired tumor, non- tumor tissues originating from each patient 
were processed to reconstruct the mtDNA genomes using the MToolBox automated 
pipeline. Pairwise comparison between blood/normal solid tissue and tumor was performed 
in order to identify the potentially germline and tumor-specific somatic mtDNA variants. 




The assembly of the mitochondrial reads showed an adequate coverage and quality 
for 104 patients. Variants were classified as pathogenic based on the allele frequency and 
disease score using the HmtVar criteria. After discarding the germline variants used in 
haplogroup classification, fixing the heteroplasmic fraction (HF) at 0.4 and prioritizing the 
variants we found 13 pathogenic/likely-pathogenic missense mutations and three tRNA 
pathogenic mutations in tRNA genes. HCC tumors presented a total of 302 somatic variants. 
After applying the same criteria, we found 24 pathogenic mutations in 22 patients. The 
burden of pathogenic mtDNA mutations resulted independently associated with a poorer 





We found 21% of HCC patients to harbor somatic pathogenic mtDNA mutations in 
their tumors. We found that these patients had a poorer survival than those harbouring 
non-pathogenic variants. mtDNA mutations could cause mitochondrial dysfunction and 







Hepatocellular carcinoma (HCC) is the most frequent form of primary liver cancer, 
ranking sixth in worldwide incidence. It is characterized by a poor prognosis and a high 
mortality rate even when detected and treated at its early stage. 1–3 
With limited loco-regional therapeutic options, having a 5-year recurrence rate as 
high as 70% for the few patients that achieve complete response,4 and only one systemic 
therapy approved, HCC remains one of the deadliest types of cancer worldwide.5,6 
An underlying chronic liver disease is present in most cases and constitutes the 
background condition leading to liver cancer7,8. The most common risk factors include 
chronic hepatitis B (HBV) and C (HCV) infections, obesity and metabolic syndrome and 
chronic alcohol intake. Out of these, hepatitis B and C are the major causes of the morbidity 
and mortality, with HBV representing the main cause for HCC worldwide. Another risk factor 
which is increasing in incidence is non-alcoholic fatty liver disease (NAFLD), mainly due to 
the increase of obesity and metabolic syndrome associated with the western diet. All of 
these factors cause a chronic injury which induces progressive liver damage leading to 
cirrhosis and ultimately liver cancer.6 
 




On a genetic level, HCC tumors presents different chromosomal alterations as well as 
somatic mutations, such as mutations in the TERT promoter (60%), TP53 (30%), CTNNB1 
(30%) and AXIN1 (10%), none of which can be used in daily medical practice as predictors of 
therapeutic outcome due to insufficient testing. Moreover, as far as molecular therapies are 
concerned, alterations involving VEGFA and CCND1/FGF19, which could be targeted by such 
therapies, have been reported but are quite rare. These aspects put HCC among the group 
of solid tumors with few somatic mutations that can be targeted by molecular therapies.9,10 
Recent progress has allowed the identification of different molecular subtypes of 
HCC which, although they corelate with clinical features, are not used in clinical practice due 
to the insufficient proof of their capacity to predict a therapeutic response.6,11 The 
molecular subtypes can be divided into two main groups: the proliferation class and the 
nonproliferation class. The first is seen more frequently in tumors originating on a chronic 
HBV infection and characterized by an aggressive clinical behavior. This molecular subtype 
includes poorly differentiated tumors with TP53 mutations, activation of various oncogenic 
pathways such as MAPK, MET and mTOR as well as chromosomal instability. Regarding the 
nonproliferation class, tumors falling in this category present a gene expression signature 
more similar to that of a normal liver tissue and present more mutations in the CTNNB1 
gene (Fig 2).12,13 
Depending on the stage, current treatments include surgical resection, liver 
transplantation, radiofrequency ablation and transarterial chemoembolization. For patients 
with an advanced disease, systemic therapies are recommended. With most drugs failing in 
phase 3 trials, Sorafenib remained the only available first line treatment for these patients 
until the FDA approval of levantinib in 2018. Unfortunately, both drugs show a moderate 
increase in survival, from 7.9 months for placebo to 10.7 months for sorafenib (SHARP trial), 
and 13.6 months for levantinib compared to 12.3 months for sorafenib (Levantinib vs 
Sorafenib non-inferiority phase 3 trial).14 For second line treatment, the first drug to be 
approved by the FDA was Regorafenib, which increased survival of patients showing tumor 





Fig 2. Molecular features of hepatocellular carcinoma12 
 
Considering the unsatisfactory results obtained with the current therapeutic 
procedures (including surgical, locoregional and pharmacological therapies), the unmet 
clinical need is the identification and correction of the mechanisms leading to HCC 
occurrence in patients at risk. Although chronic liver disease, especially in the cirrhotic stage 
is the most common background condition, the explanation why some patients will develop 




The role of mitochondrial metabolism in cancer 
The process of malignant transformation describes the transformation of a normal 
cell into a neoplastic one, which by gaining additional alterations, achieves the limitless 
potential to replicate, disseminate and metastasize. In probably what is the most influential 
review in the field of oncology, Hanahan and Weinberg defined six major hallmarks of 
cancer: increased proliferation, insensitivity to growth suppression signals, resisting 
apoptosis, unlimited replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis. Later, in their second review, they add two new hallmarks: reprogramming of 
metabolism and the capacity to evade immune response (Fig 3).16–18  
 
Otto Heinrich Warburg was the first to reveal that cancers go through metabolic 
reprogramming by observing that they are characterized by an elevated level of glucose 
uptake and its conversion to lactate through glycolysis even in the presence of oxygen.19 The 
phenomenon called “aerobic glycolysis” would be later termed the Warburg effect. This 
discovery allowed the development of the 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) 
positron emission tomography (PET), an extensively used imaging technique in the clinics for 
the detection and follow-up of tumors.20  
 
Fig 3. The hallmarks of cancer.17 
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For a long period of time cancer cells have been thought to rely only on glycolysis to 
supply their energetic demands. Thus, the metabolism of cancer cells has been thought to 
be independent of the mitochondrial status, as they were considered insufficient to satisfy 
the energetic demands of a cell with such an accelerated proliferation rate. Moreover, the 
Warburg effect suggested that the increased glycolysis in cancer cells was in fact due to 
damaged mitochondria. Later, different studies have shown that many tumors still retain a 
functional mitochondria which allows them to use both glycolysis and oxidative 
phosphorylation (OXPHOS) in order to adapt to the harsh microenvironment conditions.21 
Mitochondria have been shown to contribute to tumoral development in different 
ways. Apart from the metabolic support in terms of ensuring appropriate redox balance and 
Krebs cycle functioning for anaplerotic biosynthetic reactions, mitochondria through the 
electron transport chain represent the main cellular source of ROS, which may exert 
mitogenic activity.22 By transferring an electron from their redox core to molecular oxygen, 
respiratory complexes I and III are capable of generating superoxide anions. In normal 
conditions, these molecules are rapidly converted to H2O2 by two superoxide dismutases, 
namely SOD1 located in the intermembrane space and SOD2 in the mitochondrial matrix.23 
In a physiological state, ROS are known to play an important role as signaling 
molecules, influencing cell proliferation and differentiation, but excessive levels can lead to 
cellular damage resulting in cell death. Nearly all cancers present high rates of ROS and also 
in parallel, increased levels of antioxidant enzymes in order to maintain the intracellular 
balance required for its function and survival.24 It is known that low concentrations of ROS 
exert a mitogenic activity by promoting cell survival and proliferation, while intermediate 
levels lead to cell cycle arrest and differentiation. But at high levels, ROS can lead to 
oxidative damage to different cellular components including DNA with the consequent 
generation of mutations. This phenomenon is thought to occur at a higher rate in the 
mtDNA because of its proximity to the source of ROS production and its lack of the complex 




Fig 4. The vicious cycle of ROS induced DNA damage. 
mitochondrial dysfunction with increased ROS production 
can induce mtDNA injury with the generation of mutations 
Growing tumors present a complex metabolic rewiring which does not resume only 
to the increased uptake of glucose and increased glycolysis. Cancers have also the capacity 
to oxidize glutamine in order to produce energy via the Krebs cycle and OXPHOS chain, as 
well as to process it reductively for the synthesis of fatty acids.27 
Metabolic reprogramming has also been seen in the case of HCC tumors. These 
tumors present the characteristic Warburg effect with the increased glucose uptake by 
upregulating glucose transporters GLUT1 and GLUT2 and an increased glycolytic rate.28 
Another alteration seen is the upregulation of hexokinase 2 isoform which is the first 
enzyme of the glycolytic pathway, its expression being associated with the pathological 
stage. Moreover, targeting of this enzyme has shown to increase the response to Sorafenib 
of HCC cells.29 
The metabolic plasticity of tumor cells allows them to adapt to conditions such as 
hypoxia and decreased availability of nutrients. In normal cells this would activate apoptosis 
resulting in cell death. However, in cancer cells the apoptotic threshold is increased by 
different mechanisms such as BCL2 overexpression. This increased resistance plays an 
important role when aiming to treat tumors, since the purpose of chemotherapeutics 
agents is to induce the death of malignant cells or a permanent growth arrest. Therefore, 
mitochondria play also a role in the cancer response to therapy, not only in its progression. 
Such an example can be seen in the case of melanoma cells which present a mutation in the 
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BRAF gene (BRAFV600E). Targeting of this mutation with vemurafenib is associated with a 
switch to a more oxidative metabolism in order to gain resistance to the treatment. This 
allows cells to be vulnerable to the inhibition of the electron transport chain using honokiol 
which can restore the response to vemurafenib.30 The switch from glycolysis to OXPHOS can 
be seen also in the case of pancreatic cancer driven by the KRASG12D mutation, as well as in 
the ablation of MYC/KRAS or MYC/ERBB2 in breast cancers.31,32 
Indeed, in the case of HCC, mitochondria have also been shown to play an important 
role in the resistance to sorafenib. For example, a study has shown that the activation of 
OXPHOS using dichloroacetate can overcome HCC’s resistance to sorafenib.33  
Considering the central role held by mitochondria in metabolic reprogramming of 
cancer cells as well as in the control of cell death, targeting this organelle in an attempt to 
cure tumors has gained popularity in the past years with positive results.22,34 Another 
example of the role of mitochondria in HCC metabolism can be seen in the case of studies 
with metformin. Metformin, an inexpensive drug frequently used in the treatment of 
diabetes, has been shown to inhibit respiratory complex I (CI), reducing tumorigenicity35–39. 
A great body of research shows an association between the use of metformin and reduced 
cancer incidence in HCC.40, 41 Metformin has been shown to inhibit HCC cells proliferation 
and migration42 as well as the recurrence of metastasis in mouse models 43 Despite these 
positive results, some findings have failed to show a benefit of the treatment,44,45 thus 
further clarifications are needed in order to understand the role of mitochondria in the 





Mitochondria are highly specialized cytoplasmatic organelles best known for their 
energy generating function in the form of ATP. They are semiautonomous organelles as they 
contain their own circular genome with a different genetic code than the nuclear one as well 
as a replication pattern independent from the cell cycle. Mitochondrial DNA (mtDNA) is a 
double stranded circular molecule with a size of approximately 16.6 kb46. It comprises a 
heavy (H) strand and a light (L) strand, names based on the asymmetrical G/C distribution 
which renders the H strand of a “heavier” molecular weight. The L strand was defined in the 
original publication as the sense strand containing the coding sequence of most of the 
mitochondrial genes. Therefore, the RNAs corresponding to these genes are transcribed 
from the H strand.47,48 
The mitochondrial genome contains 37 genes of which thirteen are coding for 
proteins participating in the OXPHOS chain (Fig 5). The rest encode for tRNAs (22 genes) and 
two rRNA (the 16s for the large subunit of the mitochondrial ribosome and the 12s for the 
small subunit). As opposed to nuclear genes, mitochondrial genes do not have introns. Apart 
from the non-coding nucleotides which separate contiguous genes, mtDNA has only one 
non-coding regulatory region, the displacement loop (D-loop). This region represents the 
site where the mtDNA replication and translation begin.49,50 
The inheritance of mtDNA has long been considered to follow exclusively a maternal 
pattern, as sperm mtDNA is removed by ubiquitination during the formation of the 
mammalian zygote. Because of the mtDNA is inherited only from the mother, usually in a 
homoplasmic state, this small molecule offers a valuable opportunity to explore 
genealogical relationships and track populational migration. Having an known mutational 
rate which is 5-10 times higher than that of the nuclear genome, mitochondria represent an 
important tool to distinguish evolutionary patterns of the human population. The lack of 
recombination of the mtDNA allows all variants to be organized in the shape of a 
phylogenetic tree, with all branched being traced back to the first ever mtDNA known as the 
mitochondrial Eve. These branches containing a specific combination of mtDNA variants 
could be labelled by a distinctive migration pattern on agarose gels upon restriction enzyme 
digestion. Therefore, these branches were named using alphabetic labels which are known 
as mtDNA haplogroups.51,52 
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Unlike the nuclear DNA, mtDNA is found in multiple copies with cells having between 
100 to 10000 copies depending on cellular energetical requirements. Homoplasmy defines 
then state in which all the mtDNA copies are identical. However, due to different factors 
contributing to an increased risk of mutational events, mtDNA can acquire different 
mutations which often co-exist together with the wild-type copies. This mixture of different 
mtDNA molecules which can be in various proportions, is defined as heteroplasmy. Because 
of the high number of mitochondrial DNA copies in a single cell, some wild type, some 
mutated, the percentage of any mtDNA variant/mutation can vary over time. Thus, a normal 
mitochondrial function can be maintained even in the presence of a pathogenic mutation, 
as long as the ratio of wild type mtDNA is high enough. When this ratio favors the mtDNA 
copies containing pathogenic mutations, the mitochondrial dysfunction caused by the 
 
Fig 5. Structure of the human mtDNA. MT-RNR1 and MT-RNR2 code for the 12S 
and 16S rRNAs subunits. MT-ND1 to 6 genes code for NADH dehydrogenase 
subunits. MT-CO1, MT-CO2, MT-CO3 - cytochrome oxidase subunits 1,2 and 3. MT-
ATP6 and MT-ATP8 genes codes for mitochondrial ATPase subunits 6 and 8. MT-
CYB gene codes for cytochrome b. The 22 tRNAs encoding genes are in red. 




alteration can become apparent and cause a visible phenotype. This phenomenon is known 
as the phenotypic threshold effect and it is characterized by a high variability between 
different mtDNA mutations as well as between different affected tissues. This threshold 
effect has been shown to vary between 20 and 98% for different mitochondrial diseases.54 
 
Fig 6. mtDNA polyploidy. Green represents wild type mtDNA while red shows mutated mtDNA. 
Mutations are required to reach a certain threshold in order to have an impact on the 
mitochondrial function55 
 
Mitochondria generate ATP through the OXPHOS reaction which is carried out in the 
internal membrane by the electron transport chain (ETC). The ETC comprises five protein 
complexes: NADH-ubiquinone oxidoreductase - complex I, succinate-ubiquinone 
oxidoreductase - complex II, ubiquinone-cytochrome c oxidoreductase - complex III, 
cytochrome c oxidase - complex IV, and ATP synthase - complex V (Fig 6). During evolution, 
the majority of the genes coding for mitochondrial proteins, including those of the ETC have 





Fig 7. The structure of the electron transport chain. 
 
Apart from ATP production, mitochondria carry out other functions such as 
maintaining the Ca2+ homeostasis, fatty acid beta-oxidation and redox signaling through the 
generation of reactive oxygen species (ROS). They also participate in certain steps of the 






Mitochondrial mutations in cancer 
Mitochondrial mutations have been described to occur in nearly 60% of all cancer 
types, but their functional role in tumorigenesis remains unclear. The lack of highly efficient 
repair mechanisms and the vicinity to the site of reactive oxygen generation renders 
mitochondrial DNA susceptible to a higher rate of accumulating mutations than the nuclear 
genome.58 
The majority of mtDNA mutations found are somatic, but in some cases germline 
variants which in the normal tissue have a low heteroplasmy can become positively selected 
in the tumoral tissue.59 
The most reported variants in cancer studies are located in the D-loop region of the 
mtDNA genome. This region is known to be highly polymorphic, and many authors fail to 
consider a proper stratification of the discovered variants, as the simple presence of a 
nucleotide change is not sufficient for its association with a cancer type. Thus, such studies 
need to be read with caution. The second most frequent mutations seen are those in genes 
coding for CI subunits, but this could be mainly due to the fact that most of the mtDNA 
genome codes for CI subunits. To date, no preferential mutational hotspot site in the 
mtDNA has been seen in cancer cells.60 
In cancers, the most frequently seen variants occurring in protein-coding genes are 
missense. This accumulation of variants with a functional impact has led to the idea that 
they might offer tumors a selective advantage. Contrarily, highly pathogenic mutations are 
contra-selected from tumors supporting the current accepted knowledge that functional 
mitochondria is needed in order to ensure the progression of the tumors. Unfortunately, 
there is a low availability of functional studies which characterizing completely the impact of 
mtDNA mutations which limits the current understanding of this topic.61 The association 
between mtDNA mutations and cancer development is a difficult task also due to the 
presence of heteroplasmy, which adds another layer of complexity. The current accepted 
view is that mtDNA mutations are not capable of inducing malignant transformation but can 
play an important role as modifiers of the tumorigenic potential. For example, mutations 
leading to a decreased efficiency of OXPHOS could be beneficial when tumors go through 
hypoxia but may impair the metastatic capacity of the tumoral cell bearing it.62,63 
Another issue contributing to the complex roles of mtDNA mutations is the fact that 
the same mutation can have opposite effects depending on the context in which it occurs. 
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For example, the mtDNA mutation present in the 143B osteosarcoma cell line has been 
shown to increase glycolytic metabolism and promote tumor progression when found in a 
heteroplasmy state, while increasing apoptotic rate and decreasing tumoral growth when 
found in homoplasmy.64,65 
Mitochondria play important roles in the metabolism of glutamine and lipids. 
Glutamine is used in the anaplerotic reactions of the TCA cycle and for the synthesis of 
nucleotides while the reprogramming of lipid metabolism is required for the synthesis of the 
lipids required to construct the cellular membranes. Because these processes are influenced 
by the functional status of the OXPHOS chain, mtDNA mutations can play an important role 
in the capacity of cancer cells to adapt to metabolic stress.66,67 
In the case of HCC, there is a limited number of studies tackling the role of mtDNA 
mutations in hepatocarcinogenesis. Firstly, many reports limit themselves to sequence only 
the D-loop regulatory region.68 This may lead to the finding of polymorphisms rather than to 
true pathogenic variants. Next, due to the lack of a proper classification and stratification of 
the variants, often studies consider all events found in the tumoral tissue and not in the 
healthy tissue to be potentially pathogenic. This issue is also present in other studies 
investigating the role of mtDNA mutations in different cancers as well.69 
An interesting finding is that of a common deletion affecting CI which is purified from 
the HCC tumors, suggesting its probable unfavorable impact on tumor progression.70 Other 
findings report a lower number of mtDNA copies which also seems to corelate with the 
clinical features.71 Overall, the scarce data available, combined with the lack of a careful 





The Cancer Genome Atlas (TCGA): a valuable resource for ‘omic studies  
The Cancer Genome Atlas (TCGA) is a joint effort between the National Cancer 
Institute and the National Human Genome Research Institute which began in 2006. By 
joining multiple research centers from diverse disciplines, the consortium managed to 
collect and analyze more than 20.000 primary cancers and their matched normal samples 
from 33 cancer types. Containing a wide array of large scale ‘omic techniques such as 
genomic, transcriptomic, epigenomic and proteomic data, TCGA is one of the most 
comprehensive and complete cancer datasets available to date.  
The data from the TCGA projects can be divided into two types: Open Access Tier 
and Controlled Access Tier: 
Open Access data tier comprises information which does not pose a risk for the 
research patient re-identificaton. Therefore, for this particular category the access does not 
require an approved user certification and are freely accessible through the TCGA Data 
Portal. 
Controlled Access data tier comprises data which are unique to an individual such as 
Individual germline variant data (SNP .cel files); Primary sequence data (.bam files); Clinical 
free text fields and Exon Array files. In order to gain access to such data, a researcher must 






The importance of mitochondria in carcinogenic processes is well known in general, 
but insufficient work is available in the literature which explores the role of mitochondrial 
metabolism in the instance of HCC development. 
 Mitochondrial mutations have been known to play a role in the process of 
carcinogenesis with many works reporting the occurrence of mtDNA mutations in tumors. 
To date, few studies correctly prioritize the mitochondrial DNA variants discovered. Thus, an 
extensive analysis of the mitochondrial status in a large dataset of patients may be an 
opportunity to discover novel mechanisms in the pathogenesis of HCC. 
 
The main objective of this study was to analyze the occurrence and role of mtDNA 
mutations in HCC tumors and to explore their value as predictive markers for HCC prognosis. 
To this purpose we first identified and defined the mitochondrial DNA mutational 
landscape in the hepatocellular carcinoma cohort from The Cancer Genome Atlas 
consortium.  
By prioritizing and stratifying the variants found based on their potential pathogenic 
impact, we aimed to analyze the potential impact of such mutations on the evolution of 





Bioinformatics analysis of mtDNA mutations 
To achieve our goal, we downloaded 
whole exome sequencing (WXS) data from 
the TCGA-LIHC project for both tumoral and 
paired non-tumoral tissues (blood or 
surrounding liver tissue) after submitting a 
project request to the NIH. 
 The .fastq files deriving from 377 
HCC patients (paired tumor and non-tumor 
tissues) were processed to reconstruct the 
mitochondrial genomes using the 
MToolBox automated pipeline.72 The 
process includes the extraction and 
assembly of mitochondrial DNA fragments 
from the off-target reads and also 
discarding the sequences originating from 
the nuclear sequences derived from 
mitochondrial DNA, namely the Nuclear mt 
Sequences (NumtS). 
In order to achieve a high level of 
accuracy of our analysis and avoid false 
positive results the quality criteria set for 
this study was as follows: 
• an average sequencing depth of the 
mtDNA sequence ≥ 30X 
• Mitochondrial DNA coverage ≥ 98% 
• Number of reconstructed mtDNA 
contigs less than 2 
After the variant calling of the 
discovered events, all variants are given a functional annotation and are prioritized in order 
 
Fig 8. MToolBox analysis workflow 
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to select those of potential clinical relevance according to the tiers reported in Table 1 and 
defined, by combining the Disease score and the allele frequency for any possible variants 
that could occur in any site of the human mitochondrial genome. The disease score for 
variants occurring in coding for protein genes is estimated acccording to the algorithm 
described in Santorsola M et al, and is based on different predictors: MutPred, HumDiv and 
HumVar-trained PolyPhen-2 models, SNPs&GO, PhD-SNP and PANTHER.73–75 The disease 
score for tRNA variants is estimated according to the algorithm reported in Di Roma MA et 
al and then improved in HmtVar. For tRNA variants the MutPred etc predictors is not 
considered. This classification criteria can be found in Table 1.  
 
  Non-synonymous variants 
 
tRNA variants 
Tier Disease Score Allele Frequency 
 
Disease Score Allele Frequency 
Polymorphic DS < 0.43 AF > 0.003264 
 
DS < 0.35 AF > 0.005020 
Likely Polymorphic DS < 0.43 AF ≤ 0.003264 
 
DS < 0.35 AF ≤ 0.005020 
Likely Pathogenic DS ≥ 0.43 AF > 0.003264 
 
DS ≥ 0.35 AF > 0.005020 
Pathogenic DS ≥ 0.43 AF ≤ 0.003264 
 
DS ≥ 0.35 AF ≤ 0.005020 
Table.1. HmtVar pathogenicity predictions 
Pairwise comparison between blood/normal solid tissue and tumor was performed 
in order to identify the potentially germline and tumor-specific somatic mtDNA variants. The 
schematic analysis workflow of this study is presented in Fig 8. 
To achieve a correct estimation of the tumoral mitochondrial mutational burden, 
heteroplasmic fractions of the variants discovered was adjusted using the estimated tumor 
purity value from TCGAbiolinks R/Bioconductor package. This value combines four 
parameters: expression profiles from 141 immune genes and 141 stromal genes, somatic 
copy-number variantion data (not available for the LIHC cohort) and 44 non-methylated 
immune-specific CpG sites.76 
Complementary analysis involving other somatic mutations was carried out using the 
Mutation Annotation Format (MAF) files available in the Genomic Data Commons Data 
Portal (CGD)77. Explorative data visualization and mining was done using the Orange3 
Methodology 
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software package from Anaconda78. Graphical representations and analyses were 
constructed in R/Bioconductor using the appropriate packages such as TCGAbiolinks79,80,81 
and the CRAN TCGA2STAT82 and in GraphPad Prism 8. 
Statistical analysis using appropriate tests was done by using IBM SPSS Statistics 
software version 20. For continuous variables Student’s T-test was used while for categorical 
variables we used Chi-Square test of Fisher’s exact test. For survival analysis, the Kaplan 
Meyer curve analysis was employed. For multivariate analysis the Cox Proportional Hazards 




Paraffin embedded tissues of patients diagnosed with HCC were obtained from the 
archives of the Pathology department of Sant'Orsola-Malpighi Hospital, Bologna, Italy. Serial 
cuts of 3um were performed from each paraffin block. Sections were deparaffinized, 
rehydrated, and retrieved using a Tris-EDTA pH 8 solution (20 min at 98*C). Primary 
antibodies were purchased from Abcam:  
For complex I - NDUFS4 mouse diluted 1/1000 (Catalog no. AB55540) 
For complex III – Core 2 (UQCRC2) mouse diluted 1/1500 (Catalog no. AB14745) 
For complex IV – COX I mouse diluted 1/1000 (Catalog no. AB14705) 
For complex V - ATPase5a mouse diluted 1/2000 (Catalog no. AB14748) 
Incubation for the primary antibody was 1h at room temperature. The reaction was 
developed with a DAB-Peroxidase Substrate Solution according to the manufacturer’s 






Evaluation of the TCGA LIHC cohort revealed 104 cases eligible for mtDNA 
mutation analysis 
The TCGA-LIHC 
cohort comprises a total of 
377 HCC cases, all of which 
were run through the 
MToolBox pipeline. A 
number of 104 patients 
fulfilled our criteria and 
were further analyzed. 
These included patients for 
which data were available 
for both tumor samples and 
for their paired non-tumoral 
control. 
The majority of the 
cases were males 
representing 71% of total. 
Mean age for diagnosis for 
males was 58.5±11.8 years 
while for females it was 
58.68±15.3 years.  
Disease stages as defined by the American Joint Committee on Cancer (AJCC) cancer 
stage manual was predominantly represented by the early stages with almost 70% of the 
patients having either a stage I or II diagnosis (Fig 9). 
Almost 80% of the patients had a documented risk for developing HCC, the most 
frequent one being alcohol consumption which was reported by 31 patients. All risk factors 





The mean minimum reading 
depth for tumoral samples was 30.5x 
while the maximum was 429.5x. The 
non-tumoral samples were 
represented by either a blood derived 
normal, solid normal tissue or both. 
Mean reading depths of these 
samples spun between a minimum of 
30x and a maximum of 642.2x. 
Detailed quality information regarding 
the samples can be found in Annex 1. 
 
 
 No of patients Percent 
Alcohol consumption 23 22 
Alcohol consumption|Hepatitis B 6 5.8 
Alcohol consumption|Hepatitis C 2 1.9 
Hemochromatosis 3 2.9 
Hepatitis B 22 21.2 
Hepatitis B|Hepatitis C 1 1.0 
Hepatitis C 8 7.7 
Hepatitis C|Hemochromatosis 1 1.0 
Non-Alcoholic Fatty Liver Disease 6 5.8 
No History of Primary Risk Factors 24 23.1 





Fig 9. Number of patients for each HCC stage. 




Non-tumor specific mutations in HCC 
A total of 1216 mtDNA germline variants recognized by the Revised Cambridge 
Reference Sequence (rCRS), the Reconstructed Sapiens Reference Sequence (RSRS) and 
macro-haplogroup consensus sequence (MHCS)83 were identified. Among these, a total of 
821 variants defined the patients haplogroups and were not considered in the subsequent 
analysis steps. A general view of the distribution of the germline variants based on their 
heteroplasmy can be found in Fig 10. 
After fixing a 
heteroplasmic fraction (HF) 
threshold of 0.4 to the 
remaining 395 variants, 381 
variants were filtered, among 
which 132 (35%) were 
synonymous, 59 (16%) non-
synonymous and 189 (50%) 
were variants belonging to the 
non-protein coding class. Five 
variants were not previously 
reported in the HmtVar 
database. Summary of the 
characteristics of the variants 
found can be seen in Table 3. 
 
After applying the 
HmtVar pathogenicity criteria 
previously described, variants were divided into four classes: pathogenic, likely pathogenic, 
likely polymorphic and polymorphic. A total of 13 non-synonymous and three tRNA 
pathogenic/likely-pathogenic mutations were found in 15 (14%) patients (Fig 11). 
 
Fig 10. Distribution of the 395 germline variants found in 
the TCGA-HCC cohort. Blue dots: polymorphic/likely 
polymorphic variants, Purple dots: pathogenic/likely 






Fig 11. Distribution of germline variants in the LIHC TCGA cohort. The majority of 














AA Change AA Var DS Pathogenicity 
LIHC_16 8505G 0.000000 1 1 MT-ATP8 2 Y47C 0.0167 0.55 pathogenic 
LIHC_19 12535T 0.001017 1 1 MT-ND5 1 H67Y 0.0141 0.72 pathogenic 
LIHC_24 8516C 0.000218 1 1 MT-ATP8 1 W51R 0.0073 0.89 pathogenic 
LIHC_37 14180C 0.003246 1 1 MT-ND6 2 Y165C 0.135 0.78 pathogenic 
LIHC_51 15617A 0.001163 1 1 MT-CYB 1 V291I 0.0059 0.76 pathogenic 
LIHC_52 15383C 0.000460 1 1 MT-CYB 1 S213P 0.0054 0.77 pathogenic 
LIHC_65 8393T 0.003342 0.94 1 MT-ATP8 1 P10S 0.124 0.67 likely_pathogenic 
LIHC_76 5979A 0.000654 1 1 MT-CO1 1 A26T 0.0132 0.73 pathogenic 
LIHC_87 9163A 0.001308 1 0.98 MT-ATP6 1 V213I 0.0022 0.81 pathogenic 
LIHC_88 5095C 0.000460 1 1 MT-ND2 2 I209T 0.0122 0.65 pathogenic 
LIHC_89 12965C 0.000048 1 0.98 MT-ND5 2 L210P 0.0022 0.72 pathogenic 
LIHC_99 9163A 0.001308 1 0.95 MT-ATP6 1 V213I 0.0022 0.81 pathogenic 
LIHC_100 8944G 0.000097 1 1 MT-ATP6 1 M140V 0.0023 0.57 pathogenic 
LIHC_58 15924G 0.033061 1 1 MT-TT 
   
0.4 likely_pathogenic 
LIHC_65 15927A 0.007581 0.97 1 MT-TT 
   
0.35 likely_pathogenic 
LIHC_67 5814C 0.003028 1 1 MT-TC 
   
0.75 pathogenic 
Table 3. Germline mutations found in HCC patients. HF: MToolBox output heteroplasmic fraction; AF: allele frequency; AA 
Var: aminoacid variability; DS: disease score. Nt Var, AA Var and AF are estimated on the basis of the human mitochondrial genomes 
annotated in GenBank and then available through the HmtDB database and hence in HmtVar. 
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Tumor specific mutations in HCC 
Tumor specific mitochondrial variants were defined as new events reported only in 
the tumoral MToolBox output and not present in the non-tumoral output. 
We detected a total of 302 mtDNA variants exclusively in 89 (86%) tumor samples. 
Fifteen patients did not present any mitochondrial variants in their tumoral tissue. 
A general overview of all the somatic mtDNA variants present in the TCGA-HCC 
cohort is illustrated in Fig 12. 
Variants were grouped into protein coding and non-protein coding variants. Protein 
coding variants were either synonymous when the aminoacid remained the same, non- 
synonymous (missense) when the nucleotidic change determined also an aminoacid change 
and nonsense if the nucleotide 
alteration induced a premature 
stop codon. 
The TCGA-LIHC cohort 
presented a total of 33 (11.7%) 
synonymous variants found in 
19 patients, and 70 (24.7%) 
missense variants in 45 patients, 
while the vast majority of the 
somatic events were present in 
the non-coding part - 180 
(63.6%) and reported in 72 
cases. From this category, the 
variants occurring in the D-loop 
or rRNAs were excluded from 
the analysis where pathogenicity 
predictions were required, as for 
these variants the the algorithm 
to estimate the disease score 
has not been designed.  
 
Fig 12. Distribution of all somatic variants found in the 
TCGA-HCC cohort. Blue dots: polymorphic/likely 
polymorphic variants, purple dots: pathogenic/likely 





 After applying the pathogenicity 
scores and filtering, a total of 70 
pathogenic mutations are left with the 
main majority being located in genes 
coding for CI proteins. Although classified 
as pathogenic or likely pathogenic, the 
simple presence of a mitochondrial 
mutation is not sufficient to induce a 
phenotype. Thus, a further filtering was 
applied namely an adjusted heteroplasmic 
fraction of 0.4 (Fig.13). The remaining 24 
mutations were distributed in 22 (21%) 
patients. Their characteristics are resumed 
in Table 4. 
One patient presented a mutation 
at position 6579A in MT-CO1 which leads 
to the gain of a premature stop codon at 
position 226 out of 513. This leads to the 
formation of a truncated protein. For 
stop-gain mutations, MToolBox does not 
calculate a disease score thus it does not 
estimate the pathogenicity of this 
particular variant. In order to gain insight 
in the possible impact of this mutation, we 
explored the phyloP and PhastCons scores 
which measure the evolutionary 
conservation of a site and the probability 
of negative selection, respectively. The 
resulted phyloP positive value of 9.4 
means that this region is well conserved 
and the PhastCons value of 1 predicts this 
mutation as deleterious. 
Fig 13. Filtering and selection of somatic mtDNA 
variants found in the TCGA-LIHC tumors 
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Mitochondrial genomes are prone to accumulate 
high levels of variants in tumoral cells. These mutations 
may serve to promote tumor cell proliferation and allow 
tumors to adapt to the microenvironment.84 We analyzed 
the distribution patterns of the somatic variants found. 
We observed that the major proportion observed in HCC 
tumors were missense variants. This suggests that tumoral 
cells have an increased tolerance for the accumulation of 
these variants. (Fig 14). 
Upon further analysis we noticed that tumors show 






Fig 15. Distribution of somatic variants in the LIHC TCGA cohort. Mitochondrial complexes I-
V are abbreviated as CI-V 
 
The majority of the somatic pathogenic mutations falls into genes coding for CI (57%) 



















Aa Var DS Pathogenicity 
LIHC_67 2723 3946A 0.40 0.47 CI MT-ND1 0.0004 0.0000 missense E214K 0.0030 0.91 pathogenic 
LIHC_40 24286 12769A 0.58 0.65 CI MT-ND5 0.0001 0.0000 missense E145K 0.0053 0.91 pathogenic 
LIHC_92 2666 3922A 0.48 0.58 CI MT-ND1 0.0000 0.0000 missense E206K 0.0013 0.89 pathogenic 
LIHC_44 5220 4950C 0.36 0.53 CI MT-ND2 0.0001 0.0000 missense S161P 0.0018 0.83 pathogenic 
LIHC_29 3176 4139T 0.87 0.92 CI MT-ND1 0.0000 0.0000 missense P278L 0.0014 0.82 pathogenic 
LIHC_104 23905 12613A 0.93 1.00 CI MT-ND5 0.0012 0.0003 missense A93T 0.0067 0.82 pathogenic 
LIHC_21 20213 11087C 0.59 1.00 CI MT-ND4 0.0098 0.0021 missense F110L 0.1348 0.81 pathogenic 
LIHC_90 24915 13042A 0.57 0.85 CI MT-ND5 0.0001 0.0000 missense A236T 0.0022 0.78 pathogenic 
LIHC_63 21667 11711A 0.99 1.00 CI MT-ND4 0.0009 0.0000 missense A318T 0.0000 0.78 pathogenic 
LIHC_62 20990 11420A 0.92 1.00 CI MT-ND4 0.0000 0.0000 missense V221I 0.0000 0.75 pathogenic 
LIHC_48 23897 12610A 0.36 0.45 CI MT-ND5 0.0002 0.0000 missense V92M 0.0022 0.69 pathogenic 
LIHC_77 23442 12419T 0.92 0.99 CI MT-ND5 0.0000 0.0000 missense K28M 0.0157 0.69 pathogenic 
LIHC_21 27085 13976C 0.25 0.48 CI MT-ND5 0.0001 0.0000 missense N547T 0.0059 0.63 pathogenic 
LIHC_97 25485 13289A 0.32 0.41 CI MT-ND5 0.0007 0.0000 missense G318D 0.0082 0.88 pathogenic 
LIHC_70 29546 15005A 0.70 0.82 CIII MT-CYB 0.0002 0.0000 missense A87T 0.0000 0.87 pathogenic 
LIHC_18 29175 14846A 0.87 0.91 CIII MT-CYB 0.0000 0.0000 missense G34S 0.0009 0.87 pathogenic 
LIHC_60 30387 15357A 0.58 0.67 CIII MT-CYB 0.0000 0.0000 missense G204E 0.0009 0.85 pathogenic 
LIHC_28 31262 15699A 0.44 0.65 CIII MT-CYB 0.0000 0.0000 missense R318H 0.0009 0.82 pathogenic 
Results 
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Aa Var DS Pathogenicity 
LIHC_104 30692 15489C 0.92 1.00 CIII MT-CYB 0.0000 0.0000 missense D248A 0.0006 0.7 pathogenic 
LIHC_5 10748 7210C 0.85 1.00 CIV MT-CO1 0.0000 0.0000 missense M436T 0.0026 0.83 pathogenic 
LIHC_34 16596 9591A 0.94 1.00 CIV MT-CO3 0.0033 0.0007 missense V129I 0.0297 0.55 pathogenic 





LIHC_44 1065 3243G 0.36 0.52 tRNA MT-TL1 0.0004 0.0001    0.8 pathogenic 
LIHC_42 6640 5549A 0.62 0.66 tRNA MT-TW 0.0001 0.0000    0.35 pathogenic 
Table 4. Pathogenic somatic mutations with an aHF≥0.4 found in the TCGA HCC patients. 
HF: MToolBox output heteroplasmic fraction; aHF: tumor purity adjusted heteroplasmic fraction; Nt Var: Nucleotide variability; AF: allele 
frequency; AA Var: aminoacid variability; DS: disease score. Nt Var, AA Var and AF are estimated on the basis of the human mitochondrial 






Adjusting for the microenvironment component of the HCC tumor increases 
mtDNA variant detection 
The structure of solid tumors comprises a mass of heterogenous cell types which can 
be divided into two distinct compartments: the parenchyma and the microenvironment. The 
parenchyma is represented by the tumoral cells while the microenvironment includes a 
variety of different types of neoplastic induced cells such fibroblasts, blood vessels and 
immune cells.85 The proportion between these two parts can vary between different types 
of cancers with some tumors displaying a more evident desmoplastic reaction, with a well-
represented stromal compartment, while in others this component will grow to a smaller 
extent. This variation, also seen in the case of tumors belonging to the same cancer type, 
represents a constant challenge in research especially when using high throughput 
techniques such as next generation sequencing as it can highly underestimate the true 
mutational load.  
 In our analyzed cohort the minimal tumor purity was 36% while the maximum was 
95% with an average of 77%. In Fig XX an overall increase in the value of heteroplasmy can 
be observed after taking into account the tumor purity correction. In order to see whether 
this adjustment influences the HF in a significant way, we conducted a two tailed Paired 
Samples Wilcoxon Test which yielded a highly significant increase between the HF values 
prior to the tumor purity adjustment and those after (p<0.0001; rs=0.99).   
 
Fig 16. Differences between MToolBox Heteroplasmic fraction (HF) output and adjusted 





A. heteroplasmy threshold =0.4 
 
% of variants potentially lost 25.5% 
D. heteroplasmy threshold =0.7 
 
% of variants potentially lost 18.5% 
B. heteroplasmy threshold =0.5 
 
% of variants potentially lost 22.5% 
E. heteroplasmy threshold =0.8 
 
% of variants potentially lost 26.9% 
C. heteroplasmy threshold =0.6 
 
% of variants potentially lost 33.3% 
F. heteroplasmy threshold =0.9
 
% of variants potentially lost 45.8% 
Fig 17. Venn diagrams representing mitochondrial variants with a major HF underestimation. 
Different thresholds of 0.4 (A), 0.5 (B), 0.6 (C), 0.7 (D), 0.8 (E), 0.9 (F) were set. 
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Germline mtDNA variants show heteroplasmic change under positive or 
negative selective pressure in HCC tumors 
Mitochondrial variants are known to be subjected to pressure selection. Mutations 
favoring tumoral adaptation to the harsh tumoral microenvironment will preferentially 
expand while those showing a disadvantage would diminish.84 We asked whether any of the 
germline variants discovered showed a heteroplasmic shift, be it negative or positive.  
For this analysis we plotted 
the tumoral HF of all germline 
variants remaining after the exclusion 
of haplogroup defining events against 
the original ones found in the non-
tumoral tissue (Fig 18). We 
considered variants showing a shift of 
40% increase or decrease in their 
heteroplasmic fraction. The majority 
of variants (95.7%) showed a low 
variation while 13 variants were seen 
to present a positive selection and 
two a negative one. Most of these 
were located in the D-loop region. 
Four variants were located in 
protein coding genes and in a tRNA 
gene, respectively. 
Two synonymous variants located in genes coding for complex I proteins show an 
increase in the tumoral sample. The A3606G variant was previously reported in a study in 






Fig 18. Germline variants which present a positive 
(green) or negative (red) selection. For the non-
tumoral sample the HF from the MToolBox output 






























T10454C ↑ 117 tRNA MT-TR 0.014 0.003  0.2 
likely 
polymorphic 







Table 5. Germline variants showing a tumoral heteroplasmic shift. 
 AA: aminoacid; syn: synonymous; mis: missense; Nt Var: Nucleotide variability; AF: allele 
frequency; DS: disease score. Nt Var and AF are estimated on the basis of the human 
mitochondrial genomes annotated in GenBank and then available through the HmtDB database 
and hence in HmtVar. 
 
The 10454C variant although scored as polymorphic 
(https://www.hmtvar.uniba.it/varCard/18707), was described as a mitochondrial tRNA mutation 
associated with non-syndromic deafness. Patients presenting this mutation showed a higher 
penetrance of the disease and an earlier age of onset of hearing loss87. It has been also 
described in Leigh syndrome88 and lung cancer89. In this the last study the authors also 
classify it as a “neutral polymorphism”. 
The 9025A variant located in the mitochondrially encoded ATP synthase 6 is the only 
protein coding variant to show a decrease in the tumoral sample and is predicted to be 
pathogenic in HmtVar although no data regarding pathogenicity are available through 







mtDNA mutations correlate with immune infiltration in HCC tumors 
The role of the tumoral microenvironment in cancer progression cannot be 
overstated. Growing evidence suggests that stromal cells and innate as well as adaptive 
immune cells can influence the proliferation and drug response of tumoral cells, with major 
impact on the outcomes of the patients.90,91 
Escaping immune control of tumoral growth is one of the hallmarks of cancer.17  The 
intratumoral level of immune infiltration has been described recently as a factor with 
prognostic value in different cancers.92,93 Exhaustion of T cells is the process in which T cells 
become dysfunctional and therefore allow tumoral immune escape.94 Elevated ROS levels in 
the tumoral microenvironment have been associated with lymphocyte inactivation and 
tumor induced immunosuppression95. Because mtDNA mutations could lead to the 
generation of higher levels of ROS96,97, we sought to evaluate whether the presence of 
pathogenic mtDNA mutations could corelate with the immune component of the tumoral 
samples. For this we made use of the paraclinical immunohistochemical data available on 
the GDC portal which contains for each tumor specimen, the percentage of immune cell 
infiltration (monocyte, lymphocyte and neutrophils) as well as the percentage of stromal 
component.80 
In the analysed TCGA HCC cohort, we first focused our attention on mitochondrial 
variants located in genes coding for subunits of CI and CIII, the main generators of ROS from 
the ETC. We observed that the HCC tumors harboring pathogenic variants had a significantly 
lower proportion of the stromal component (p-value for Student’s t-test = 0.01) as well as a 
lower level of lymphocytic infiltration (p=0.05). When analyzing each complex separately, 
only mutations located in CI genes reached statistical significance for both the stromal 
component as well as for lymphocyte infiltration (p-value=0.05 for both).  
Regarding the impact of variants situated in genes coding for other components of 
complexes or for tRNA genes, the p-value remained not significant although a positive trend 


















Fig 19. Somatic complex I mutations correlate with 
the level of intratumoral stromal component (A), 
lymphocyte infiltration (B), neutrophils (C) and 
monocytes (D). 
Mitochondrial complexes I-V are abbreviated as CI-V 
 
Of note, for mutations located in CV genes we could not conduct any analysis as the 
non-pathogenic group comprised only one tumor sample. 
 
Pathogenic mtDNA mutations predict overall survival of TCGA LIHC patients 
Because of the known pro-tumorigenic effects of some mtDNA mutations, we sought 
to analyze the possible relationship of pathogenic mtDNA mutations on different clinical 
features of HCC samples.  
First we analyzed whether the somatic mutations presented a different distribution 




Fig 20. Distribution of non-pathogenic (A) and pathogenic 
(B) somatic mtDNA mutations between patients having 
different stages of HCC. 
Mitochondrial complexes I-V are abbreviated as CI-V 
 
Chi-square test showed no significant difference in the distribution of pathogenic 
mtDNA mutations between the stages of HCC. The analysis was conducted only for stages I, 
II and IIIA, as the only two patients having stage IIIB of the disease showed only non-
pathogenic mtDNA variants. Because tumoral resection, hence access to tumoral tissue for 
the analysis, is recommended for early stages of the disease, samples from advanced stages 
are often limited, as seen also in this cohort. Thus, a comprehensive analysis of the 
mutational burden between diferent stages cannot be fully carried out. 
We next sought to see if the presence of pathogenic mutations was influenced by 
any of the backgound risk factors present in the HCC patients. Again, the Chi-Square test 





Fig 21. Distribution of non-pathogenic (A) and pathogenic (B) mtDNA mutations 
between patients with HCC developed on different backgound conditions. 
Alc: Alcohol consumption; H: Hemochromatosis; HepB: Hepatitis B; HepC: 
Hepatitis C; NAFLD: Non-Alcoholic Fatty Liver Disease; None: Absence of a 
background condition. Mitochondrial complexes I-V are abbreviated as CI-V 
 
We then proceeded to see whether the presence of a pathogenic mtDNA mutation 
in tumors would change the survival outcome of the TCGA-HCC patients. The required 
information was available for 102 out of 104 patients. Survival analysis was performed 
between the group of patients carrying a pathogenic mtDNA mutations and those carrying 
non-pathogenic variants. 
Given the known threshold effect presented by mtDNAmutations, in order to avoid 
selecting a random threshold to analyze our data, we used different adjusted heretoplasmy 
thresholds in the range of the values reported in literature. Thus, the following Kaplan-
Meyer survival analyses were conducted using thresholds values between 0.4 and 0.9 aHF 
(presented in Fig 22). For all survival curves, patients harboring non-pathogenic 
mitochondrial mutations presented statistically significant higher survival rates when 
compared to their counterparts with pathogenic mutations (p values < 0.05 for all curves). 
Because of the small number of patients available for the analysis, the median 
survival times could not be calculated for the non-pathogenic patients groups, therefore in 
order to evaluate the average survival of the two groups we calculated the estimated mean 
Results 
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survival times for each group. Since time is a type of variable with a non-normal distribution, 
this limitation of the analysis could represent a source of bias. The results are resumed in 
Table 6. It can be noted that no matter the heteroplasmy threshold set for analysis, the 
patients harboring non-pathogenic variants presented a significantly longer survival time.  
 
 
 Mean  
Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
aHF≥0.4     
non-pathogenic 2084.241 220.169 1652.710 2515.772 
pathogenic 1362.300 257.771 857.069 1867.532 
aHF≥0.5     
non-pathogenic 2047.198 241.950 1572.976 2521.419 
pathogenic 1358.512 286.210 797.540 1919.484 
aHF≥0.6     
non-pathogenic 2199.714 208.574 1790.909 2608.519 
pathogenic 1110.908 251.429 618.107 1603.709 
aHF≥0.7     
non-pathogenic 2162.167 239.933 1691.898 2632.435 
pathogenic 1231.833 320.467 603.717 1859.950 
aHF≥0.8     
non-pathogenic 2162.167 239.933 1691.898 2632.435 
pathogenic 1195.875 323.836 561.156 1830.594 
aHF≥0.9     
non-pathogenic 2109.600 282.102 1556.679 2662.521 
pathogenic 1519.500 341.250 850.650 2188.350 









Fig 22. Survival analysis of TCGA-HCC patients with different aHF thresholds of 0.4 (A), 0.5 (B), 0.6 






In order to evaluate whether survival was influenced by other factors and their effect 
size, we performed a multivariate analysis using Cox regression model. To identify 
covariates which could potentially affect patient prognosis we considered for the analysis 
the following variables: age at diagnosis, gender, AFP levels, stage and microvascular 
invasion. In order to select the significant variables to introduce in our model we first 
performed separate univariate analysis. Gender attained statistical significance for aHF 
thresholds of ≥0.5 (p<0.01) , ≥0.6 (p<0.02), ≥0.7 (p<0.03) and ≥0.8 (p<0.03) while all other 
variables remained unsignificant for every heteroplasmy fraction threshold. 










1.008 0.066 2.739 0.936-8.016 





1.136 0.043 3.113 1.035-9.366 





1.348 0.023 3.850 1.204-12.308 





1.922 0.021 6.831 1.341-34.800 





1.910 0.019 6.754 1.361-33.510 





1.068 0.288 2.911 0.406-20.883 
Gender -1.339 0.145 0.262 0.043-1.588 
Table 7. Multivariate Cox regression analysis of overall survival of HCC patients included in 
the study 
We can see that carrying pathogenic mtDNA mutations significantly increases the 
death hazard ratio for all the aHF thresholds between 0.5 and 0.8. Harbouring somatic 
mtDNA mutations was associated with a risk of death up to 6.8 times higher for a aHF≥0.7. 





It is known that prognosis of HCC patients is influenced by the stage of the disease. 
We can observe this trend also in the HCC cases studies here albeit not statistically 
significant (Fig 23). 
 
Fig 23. Survival of the TCGA HCC patients based on 
the stage of the disease 
We therefore sought to analyse whether the presence of pathogenic mtDNA 
mutations was also capable of influencing the prognosis of the different stages of the 
disease. 
The analysis was possible only for mtDNA variants with a aHF>0.4, as filtering further would 





Fig 24. Survival of patients with different HCC stages based on 
the burden of pathogenic mtDNA mutations 
The significance was not calculated due to the small number of patients in each 
subgroup, a trend can be observed further confirming the prognostic value of pathogenic 





TP53 status predict overall survival independent of mitochondrial DNA 
mutations burden 
The TP53 gene is the most frequently mutated gene in tumors. Out of all 104 HCC 
patients, 24 (23%) presented mutations in the TP53 gene (Fig 25). The missense c.747G>T 
which changes the Arginine in position 249 to a Serine was seen in 4 patients. This mutation 
is frequently seen as a consequence of exposure to aflatoxin B1. Exposure information is 





Fig 25. A. Number of patients carrying TP53 mutations. B. TP53 mutations present in our 
analyzed patients 
 
To gather information about these mutations, including pathogenicity predictions, 
we queried the IARC TP53 database (http://p53.iarc.fr/) which contains information 
regarding TP53 mutations associated with human cancers that have been either curated 
from genomic databases or published in peer reviewed papers (Table 8) 
The majority were in the DNA binding domain of the protein and had an impact on 
the transactivational capacity of reported genes under the control of a p53-response 









Polyphen2 Transactivation Class 
Loss of growth 
Suppression 
c.823T>C p.C275R missense yes DNA binding D D non-functional DNE_LOF 
c.610G>T p.E204* nonsense no DNA binding 
   
notDNE_LOF 
c.772G>A p.E258K missense yes DNA binding D D non-functional DNE_LOF 
c.812A>T p.E271V missense yes DNA binding D D non-functional DNE_LOF 
c.1021T>G p.F341V missense no Tetramerisation D B partially functional notDNE_LOF 
c.578A>G p.H193R missense yes DNA binding D D non-functional DNE_LOF 
c.406C>T p.Q136* nonsense yes DNA binding 
   
notDNE_notLOF 
c.467G>C p.R156P missense no DNA binding T D non-functional DNE_LOF 
c.638G>A p.R213Q missense yes DNA binding D D non-functional DNE_LOF 
c.743G>A p.R248Q missense yes DNA binding D D non-functional DNE_LOF 
c.747G>T p.R249S missense yes DNA binding D D non-functional DNE_LOF 
c.839G>A p.R280K missense yes DNA binding D D non-functional notDNE_LOF 
c.757A>G p.T253A missense no DNA binding D D non-functional DNE_LOF 
c.469G>T p.V157F missense yes DNA binding D D non-functional unclass. 
c.589G>T p.V197L missense yes DNA binding D D partially functional unclass. 
c.376-1G>A p.X126_splice splice no 
     
c.560-1G>A p.X187_splice splice no 
     
c.97-1G>A p.X33_splice splice no 
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Polyphen2 Transactivation Class 
Loss of growth 
Suppression 
c.614A>C p.Y205S missense yes DNA binding D P non-functional DNE_LOF 
c.659A>G p.Y220C missense yes DNA binding D D non-functional DNE_LOF 
Table 8. Characteristics of the TP53 mutations present in the HCC cohort. 
HGVS: Human Genome Variation Society; SIFT Class D: Deleterious, T: Tolerated; Polyphen2 D: probably damaging, P: Possibly damaging, B: 





Apart from the classical roles played “as the guardian of the genome”, p53 has been 
shown to be involved also in the regulation of metabolism and mtDNA proofreading. Thus, 
we investigated whether the mutational status of TP53 correlated with the presence and 
number of mtDNA mutations.  
For this analysis, we included all somatic variants discovered with an aHF higher than 0.1 to 
exclude false positive variants possibly due to sequencing errors. We observed a slight 
increase in the overall number of mtDNA variants as well as of the mtDNA pathogenic 




Fig 26. Proportion of mitochondrial variants in HCC patients with 
different TP53 status. A. All discovered somatic variants with an 
aHF>0.1 (WT[green] are patients without any mtDNA somatic events). 









Given the known influence of TP53 mutations survival of cancer patients, we sought 
to analyze whether in our cohort of HCC patients TP53 would have an impact on the overall 
survival regardless of the burden of mtDNA mutations. The Kaplan-Meyer curve shows that 
patients with a mutated TP53 had a significant poorer prognosis p=0.007 (Fig 27). 
 
Fig 27. Survival of HCC patients with wild-








Sources of mtDNA damage in the LIHC-TCGA cohort 
Mutations in the mitochondrial genome are known to occur at a much higher rate 
than in the nuclear genome. One of the currently accepted explanations for this observation 
is that the close proximity of the mtDNA to the OXPHOS chain renders it more vulnerable to 
oxidative damage induced by ROS which in tumors are known to reach higher levels. On the 
other hand, these mutations can be attributed also to polymerase gamma (POLG) 
replication errors, as the mitochondrial do not benefit from the complex DNA repair 
mechanisms of the nuclear DNA. 
Mitochondria through their activity of oxidative phosphorylation represent the main 
cellular generators of ROS, which can ultimately induce mtDNA injury. The currently 
accepted oxidative damage signature is characterized by the high rate of G:C to T:A 
transversions via the generation of 8-hydroxy-2'-deoxyguanosine (8-oxo-dG). Moreover, 
ROS may induce damage to the dGTP pool with the generation of 8-OH-dGTP. This leads to a 
transversion from A:T to C:G in the mtDNA genome.  
The second source for the occurrence of mtDNA mutation is the erroneous DNA 
replication due to polymerase errors, especially in the homopolymeric regions. Indeed, 
mutations in the POLG gene have been associated with increased levels of mtDNA 
mutations.98,97 Moreover, mutations in this gene have been shown to occur in 63% of breast 
tumors leading to mtDNA depletion as well as increased tumorigenicity.99 This mutational 
pattern is characterized by C>T and A>G substitutions.98  
 We sought to analyze whether the somatic mutations found in our patients follow 
such DNA damage models and found that 53% of all events were represented by the G>A 
transition. A major part of these changes was seen in genes encoding for CI subunits. The 
second most frequent base change seen was T>C representing 20%, followed by C>T in 15%. 
The A>C and C>A changes represented only 5.5% of all the mtDNA alterations. 




Fig 28. Number of somatic transitions and transversions 
present in our HCC cohort. 
To further investigate the possible causes which might explain the accumulation of 
such mutations in these patients, we controlled for the presence of mutations in genes 
responsible for ROS detoxification and for mtDNA replication machinery. We proceeded to 
extract the somatic mutations of our genes of interest from the .maf files.  
We searched for enzymes involved in ROS-detoxification and homeostasis on Gene 
Ontology (GO) knowledgebase (http://www.geneontology.org/) and on Kyoto Encyclopedia 
of Genes and Genomes (KEGG) (http://www.genome.jp/kegg/)100 we selected the following 
list of 36 genes: 
 
Gene Ensembl ID Gene Ensembl ID 
GLRX1 ENSG00000173221 TXNDC2 ENSG00000168454 
GLRX2 ENSG00000023572 TXNDC3/NME8 ENSG00000086288 
GLRX3 ENSG00000108010  TXNDC5 ENSG00000239264 
GLRX5 ENSG00000182512  TXNDC6/NME9 ENSG00000181322 
GRXCR1 ENSG00000215203 TXNDC8 ENSG00000204193 
NOS1 ENSG00000089250  TXNDC9 ENSG00000115514 
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NOS2 ENSG00000007171  TXNDC11 ENSG00000153066 
NOS3 ENSG00000164867  TXNDC12 ENSG00000117862 
PRDX1 ENSG00000117450  TXNDC15 ENSG00000113621 
PRDX2 ENSG00000167815  TXNDC16 ENSG00000087301 
PRDX3 ENSG00000165672  TXNDC17 ENSG00000129235 
PRDX5 ENSG00000126432  TXNL1 ENSG00000091164 
PRDX6 ENSG00000117592  TXNL4A ENSG00000141759 
SOD-1 ENSG00000142168 TXNL4B ENSG00000140830 
SOD-2 ENSG00000112096  TXNRD1 ENSG00000198431 
SOD-3 ENSG00000109610  TXNRD2 ENSG00000184470  
TXN ENSG00000136810  TXNRD3 ENSG00000197763  
TXN2 ENSG00000100348  TXNIP ENSG00000265972  
 
We found 13 single nucleotide variations distributed in 11 patients. Eight variants 
were missense mutations with 6 having a pathogenic SIFT/Polyphen prediction (Table 9 A). 
Given the small number of these patients no differences in the distribution of mtDNA 
variants was seen (Fig 29). Moreover, upon closer analysis we saw that only two of these 
patients had an alteration typical of ROS induced DNA damage. This leads us to conclude 
that, at least in this cohort of HCC patients, mutations in genes coding for enzymes 
responsible for ROS detoxification are not responsible for the mtDNA mutations found. 
 
Fig 29. Distribution of mtDNA mutations between patients 
with and without mutations in antioxidant genes.  
N: no; Y: yes 
Results 
57 
Next, we searched for mutations in the POLG gene as well as in other genes encoding 
for the mitochondrial DNA replication machinery.  








LIG3  ENSG00000005156 
mtSSB ENSG00000106028 
 
We found that out of all the 377 LIHC patients on TCGA, only 14 patients presented 
variations in the selected genes and out of these, only three patients were present in our 
cohort. These patients did present also mtDNA variants characterized by a C>T change. 
While mutations in genes encoding components of the mtDNA replication machinery might 
explain the occurrence of mtDNA mutations in these patients, it does not offer an 
explanation for the variants seen in the other patients. Thus, we cannot attribute the 
number of mtDNA mutations in the TCGA-LIHC cohort to mutations. 







Gene dbSNP HGVSc HGVSp Consequence SIFT PolyPhen IMPACT COSMIC 
GRXCR1 novel c.619T>A p.Y207N missense 
Deleterious 
(0.02) 
D (0.999) MODERATE  
NME8 novel c.444T>C p.C148C synonymous   LOW  
NME8  c.157A>T p.K53* stop_gained   HIGH COSM4923173 
NOS1  c.1254G>A p.S418S synonymous   LOW COSM1359118 
NOS1  c.2444G>T p.G815V missense 
Deleterious 
(0) 
D (0.999) MODERATE COSM4925301 
NOS2 rs759255233 c.1824G>A p.S608S synonymous   LOW  
NOS2 novel c.2013C>A p.S671R missense 
Tolerated 
(0.18) 
P (0.58) MODERATE  
NOS2  c.2824G>A p.G942S missense 
Deleterious 
(0) 
D (0.974) MODERATE COSM4937890 
NOS3 novel c.720C>A p.D240E missense 
Deleterious 
(0.03) 
D (0.98) MODERATE  
NOS3 rs145811781 c.1296G>T p.E432D missense 
Tolerated 
(0.08) 
D (0.99) MODERATE  
PRDX6 novel c.521G>A p.R174K missense 
Tolerated 
(1) 
B (0) MODERATE  
TXN2 novel c.388G>C p.V130L missense 
Deleterious 
(0) 
P (0.859) MODERATE  
TXNDC2 novel c.279A>C p.S93S synonymous   LOW  
B. 
FEN1 rs573495657 c.1016G>A p.R339H Missense 
Deleterious 
s(0) 
D (0.993) MODERATE COSM1355266 
LIG3 novel c.2011C>T p.R671W Missense 
Deleterious 
(0) 
D (1) MODERATE  
LIG3 novel c.2743G>T p.V915L Missense 
Tolerated 
(0.54) 




Gene dbSNP HGVSc HGVSp Consequence SIFT PolyPhen IMPACT COSMIC 
LIG3 rs761685440 c.1427C>T p.S476L Missense 
Deleterious 
(0.01) 
B (0.068) MODERATE 
COSM3819302 
COSM3819303 
POLG2 novel c.438G>T p.R146S Missense 
Deleterious 
(0.01) 
D (0.92) MODERATE  
POLG2 novel c.438G>T p.R146S Missense 
Deleterious 
(0.01) 
D (0.92) MODERATE  
Table 9. Summary of variants located in ROS detoxifying genes (A) and in genes encoding for components of the 
mitochondrial replisome found in HCC patients.  





HCC patients present also mutations in OXPHOS genes encoded by the 
nuclear genome 
Studies tackling the subject of mutations involving the respiratory chain often focus 
only on those found in the mitochondrial genome and leave behind the many OXPHOS 
genes coded by the nuclear genome. This might be justified by the fact that given the 
particular vulnerability of the mtDNA to the acquisition of mutations, a tumor is more likely 
develop OXPHOS impairment due to mutations in the mtDNA rather than in the nuclear 
one. Nevertheless, such an approach might miss out some valuable information. Therefore, 
to have a complete view over the mitochondrial mutational status, we sought to see 
whether any of the patients presented mutations in mitochondrial proteins encoded by the 
nuclear DNA. For this purpose, we selected genes included in the KEGG OXPHOS pathway 
dataset. All genes were listed also in the MitoCarta 2.0, an online resource comprising genes 
with strong evidence of mitochondrial localization.101 
We found a total of 34 single nucleotide variations in the tumoral samples of 30 
patients. Out of the 21 located in coding regions, five were mutations predicted to be 
pathogenic by both SIFT/Polyphen. Four patients presented mutations in both 













Location Gene Consequence dbSNP HGVSc HGVSp SIFT PolyPhen IMPACT 
CI NDUFS1 missense novel c.1697T>G p.I566S deleterious(0) D (0.925) MODERATE 
CI NDUFB5 missense novel c.413C>T p.A138V deleterious(0.01) P (0.493) MODERATE 
CV ATP6AP1 missense 
 
c.229T>A p.Y77N deleterious(0) D (0.993) MODERATE 
CV ATP6V1B2 missense 
 
c.563A>C p.K188T deleterious(0) D (0.996) MODERATE 
CV ATP6V1B1 missense novel c.883A>C p.S295R deleterious(0) D (0.978) MODERATE 
Table 10. Variants found in nuclear encoded mitochondrial genes. Polyphen D: probably damaging, P: Possibly 




Livers with HCC present a heterogenous staining for mitochondrial complexes 
Mutations affecting genes coding for OXPHOS chain complexes can cause the 
disassembly of the respective complex resulting in the disruption of the respiratory 
chain.102,103 Given the considerable number of mtDNA mutations found previously, we 
sought to see whether by staining HCC tumors and surrounding non-tumoral tissues for 
mitochondrial complexes, we could find a possible hint of such defects. We noticed that 
both non-tumoral as well as tumoral tissues presented a heterogenous pattern of the 
staining. However, there was a difference between the two: in the non-tumoral tissue there 
was a well delimited border between the intensely stained zones and the weakly/negatively 
stained areas, whereas the tumors were exibiting a more disorganized pattern, with a 
mixture of cells showing an intense staining with those with a lower staining intensity. 
Another observation that can be made is that the non-tumoral tissue seems to 
display a gradient in staining intensity, with a lower intensity towards the central part of the 
tumoral mass. This phenomenon was seen more intensely in the case of sample no 4 and 5, 
where at the line of interface with the stromal component, the tumor presented a much 
highly intense signal than in the rest of the mass. This could be explained by the fact that as 
tumors grow, the center becomes hypoxic forcing cells to rely more on glycolysis as the 
oxygen demand by the OXPHOS chain is not fulfilled. 
Next we sought to confirm the presence of mtDNA mutations in the nodules and 
areas showing a different staining pattern but unfortunately, the small size of the nodules 
and limited available tissue combined with the long storage of the samples did not allow for 
a DNA extraction of a sufficient quality and quantity for the amplification of the 
mitochondrial genome. Thus, we can only suppose that these patterns could be due to the 
presence of mtDNA mutations. 
Fig 30 presents the pattern of immunohistochemical staining of mitochondrial 
complexes at 10x (A) and 40x (B) magnification. The non-tumoral surrounding tissue is on 









Sample 1 A. 10x B. 40x 

















Light green arrows show well delimited areas of weak/negative 
staining in the non-tumoral tissue. 



















Fig 30. Staining pattern of mitochondrial proteins in HCC tumors 
Results 
64 
Sample 2 A. 10x B. 40x 

















Sample 3 A. 10x B. 40x 























Sample 4 A. 10x B. 40x 
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 Blue arrows indicate the increased staining intensity presented by the tumoral 
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Sample 7 A. 10x B. 40x 





















Sample 8 A. 10x B. 40x 






















The study of mtDNA mutations and their functional impact in different diseases 
including cancer continues to remain a challenge despite technological advancements in the 
field of genetics and molecular biology.  
In this work, we extracted mtDNA variants from WXS data of the TCGA LIHC cohort 
using MToolBox pipeline. We report a high number of mtDNA variants found in the analyzed 
HCC patients, among which 21% of the harbored tumor variants were deemed as 
pathogenic. 
Discussing the impact of mtDNA mutations in cancer is difficult to summarize and 
estimating their impact on the clinical outcome of cancer patients is even more challenging 
due to several issues present in literature. First, many papers define a mtDNA mutation as 
any variant found in the tumor sample and not in the paired non-tumoral tissue. But this 
simple occurrence of a mtDNA variant in a tumor does not necessarily imply its 
pathogenicity. This aspect seems to not be fully understood by some authors. Also, some 
papers analyze only tumoral tissues, thus making it impossible to conclude whether the 
variants found are somatic or germline. Other approaches include deeming variants as 
“novel” if they were not found in the MITOMAP database, which although extensive, does 
not index all variants reported in healthy individuals. In the absence of a further evaluation 
and a proper pathogenicity scoring, these variants may be wrongly regarded as pathogenic 
by the authors. 104 Moreover, some reports have shown that in some papers the variational 
patterns which include different haplogroups sites being present in the same sample would 
be more likely explained by technical errors rather than real events.105 A further problem is 
the focus of many works on variants present in the variable regions of the mtDNA, namely 
the D-loop. This site is the major regulatory region of the mtDNA and it contains many sites 
of functional relevance. The polymorphic sites are located inside the HVSI and HVSII regions 
which represent the markers used to assign the haplogroups before the era of the 
seuqencing of the entire mitochondrial genome. Thus, many variants reported here are also 
present in the normal healthy population. Another layer of complexity when dealing with 
mtDNA mutations is added by the presence of heteroplasmy. Thus, the simple relationship 
between the mere presence of a mutation causing a defective respiratory chain and the 
occurrence of a specific phenotypical sign has remained problematic as many authors fail to 
consider this aspect. 
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In this work we considered all the aforementioned limitations and provided a 
thorough analysis of the variants discovered. First, we included in the analysis only the 
patients for which good quality sequences were extracted from both tumoral and non-
tumoral sample. This allows for a correct differentiation between germline variants and 
somatic ones. Next, we discarded samples which have shown different haplogroups as such 
a situation would be impossible to find in a normal setting. Moreover, the ambiguous 
assignment of more haplogroups does not guarantee good assembling and mitochondrial 
DNA coverage. Moreover, the non-synonumous mutations found were considered 
pathogenic based on the HmtVar disease score which uses the pathogenicity prediction 
given by six tools associated to the allele frequency observed in healthy subjects.106,107,83 All 
of this, together with discarding of the variants with a low heteroplasmy ensure a minimal 
level of false positive variants. 
The mitochondrial genome of HCC tumors shows an increased tendency of 
accumulating mutations, but the functional impact of such mutations is yet to be fully 
understood. Moreover, given the polyploid nature of the mtDNA, such mutations are often 
found in a heteroplasmic state. This allows cells having mtDNA mutations which offer a 
metabolic advantage to prevail, while those bearing unfavorable variants will subside. The 
result is seen as a shift in heteroplasmy and in our cohort was analyzed in the case of 
germline mutations. Although many variants presented a different value of HF between the 
non-tumoral and the tumoral tissue, only in the case of few mutations was this variation 
present to a greater extent. The three variants which shown a positive selection were 
considered likely polymorphic. A closer analysis in literature has found that these variants 
have been reported in different diseases such as diabetes, deafness or cancer, but given the 
lack of a proof for a functional role, a simple co-occurrence of a mtDNA variant with a 
disease is not enough. Even though the selection of a mtDNA variant in a tumor might lead 
to the instinctive thought that it could somehow favor tumoral development, mathematical 
models have shown that a variant can arrive to higher heteroplasmy levels, even 
homoplasmy, by chance.108 Regarding negative selection one mutation in CV presented a 
decrease in HF in the tumoral sample when compared to the non-tumoral tissue. The reason 
behind the counterselection of such a variant might rely in the function of the complex 
itself. While mutations occurring in other mitochondrial complexes might cause a mild 
OXPHOS impairment, a mutation in CV, the place of ATP synthesis, could lead to a severe 
energy imbalance which would be detrimental for the cancer cell. But what about the other 
germline pathogenic mtDNA mutations which do not seem to present any variation in HF? In 
the HCC patients analyzed we observed six such mutations. There is interesting in vivo data 
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showing that some mutations occurring in CV might actually increase the tumor fitness 
favoring its growth as well as causing resistance to apoptosis. 109–111 This might also be the 
case of the mutations in CV reported in this study. 
Some of the somatic mtDNA mutations found in the studied patients have been 
reported previously in literature in mitochondrial diseases. For example, the 3946A in the 
MT-ND1 gene and the 3243G  mutation from the MT-TL1 gene were found present in 
patients diagnosed with MELAS, the latter accounting for up to 80% of diagnosed cases.112 
The 3243G mutation in the MT-TL1 gene could impact the synthesis of mitochondrial 
complexes subunits causing mitochondrial dysfunction and probably a deficient tumoral 
growth. 
Another mutation found, the 13042A in the MT-ND5 gene, has been previously 
reported in patients with LHON‐like optic neuropathy.113 
The 14846A mutation in the MT-CYB gene previously reported in patients with 
exercise intolerance has also been found in one HCC tumor.114 
Apart from the OXPHOS mutations found in the mtDNA genome, we also report few 
patients carrying mutations in the OXPHOS coding genes from the nuclear genome. We 
found five pathogenic mutation in CI and CV genes. Mutations in the OXPHOS genes 
encoded by the nucleus are often overlooked in cancer studies. Depending on their site of 
occurrence, mutations in the OXPHOS chain can have a different impact. While CI and CIII 
mutations might increase ROS levels and offer a tumoral advantage, mutations in CV can 
result in a decreased ATP supply which would represent a disadvantage for the cancer cells. 
Regarding the impact of mutations in nuclear OXPHOS genes, a study on families with a 
genetically established OXPHOS deficiency has shown that patients owning their disease to 
a mutation occurring in a nuclear gene coding for OXPHOS proteins have an earlier age of 
onset and present a more severe clinical course.115 In the case of cancer patients, larger 
studies are required to be able to analyze the influence of such mutations on cancer 
progression. 
One of the most studied proteins in cancer, p53 encoded by the TP53 gene, carries 
out numerous cellular roles including cell cycle regulation, DNA damage repair and cell 
death. TP53 is the most mutated gene in cancer showing a frequency of over 30% on the 
COSMIC database. These mutations are mainly missense mutations located in highly 
conserved functional parts of the protein, unlike the deletions of frameshifts usually 
reported in other tumor suppressor genes. This, together with the fact that until now there 
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are no reports of inactivation of p53 by hypermethylation hints toward the idea that mutant 
variants of p53 could play a role in tumorigenesis.116,117. Even though in HCC TP53 is the 
third most frequently mutated gene after TTN and CTNNB, this value remains rather low 
(20-30% vs 60-80% as in colon, lung or skin cancer for example). A recent study in cell 
reports comes forward to provide insight into this paradoxically retained wild-type p53 by 
showing its role in increasing glycolysis and suppressing pyruvate-driven oxidative 
phosphorylation by upregulating PUMA.118 This finding comes in contradiction with the 
commonly accepted idea that wild-type p53 supports oxidative metabolism. Control of 
glucose metabolism is one of the many non-canonical roles of p53. It has been shown in 
many papers that p53 inhibits glycolysis by targeting multiple steps, even leading to an 
attenuation of the Warburg effect. First, it has a suppressive effect on the main cellular 
glucose transporters (GLUT1 GLUT3 and GLUT4) and represses the promoter of the insulin 
receptor (INSR) to limit the entry of glucose inside the cells. Moreover, by repressing the 
transporter of lactate, monocarboxylic acid transporter 1 (MCT1), it causes an build-up of 
lactate inside the cell which will consequently limit the glycolytic rate.119 Another 
mechanism deployed to inhibit glycolysis is by inducing the TP53-induced glycolysis and 
apoptosis regulator (TIGAR). TIGAR dephosphorylates fructose-2,6-bisphosphate (F2,6P2) 
into fructose-6-phosphate (F6P) which is later converted to fructose-1,6-bisphosphate 
(F1,6P2) by phosphofructokinase-1 (PFK1). This conversion is a rate limiting reaction in 
glycolysis. Furthermore, p53 plays a role in the assembly of the CIV subunit, by activating 
the transcription of the cytochrome c oxidase assembly protein (SCO2).120,121 
Another recently discovered role of p53 was that of proofreading and maintaining 
the integrity of the mtDNA genome, a role long thought to be held only by POLG1. This 
POLG1 independent repair mechanism has been shown in pol-g proofreading deficient mice 
prone to the accumulation of mtDNA mutations 122 Because of this role we expected to find 
an increase in the number of mutations found in tumors harboring TP53 mutations. While 
the mutated samples did show a small tendency towards an accumulation of mtDNA 
variants, it did not reach a statistically significant difference. This could be due to the small 
number of patients having a mutated TP53 being compared with a much higher number of 
patients with the wild type. Another reason could be the fact that TP53 mutations, with the 
exception of aflatoxinB1 induced HCCs, can occur as a late event in the tumorigenesis of 




The hotspot mutation R249S seen in 4 patients is associated with Aflatoxin B1 
exposure which is a risk factor for HCC. The exposure data available on the CGD portal is 
scarce thus a direct association with this issue was not possible, but a study identified the 
Aflatoxin B1 Mutational signature (COSMIC signature 24 - 
https://cancer.sanger.ac.uk/cosmic/signatures_v2) is these patients124. Aflatoxin B1 
exposure has been described to cause a significant level of mitochondrial dysfunction with 
induction of ROS generation and activation of apoptosis125,126 but associations with mtDNA 
mutations have yet to be investigated. 
Increased production of ROS could also be a possible contributor to the 
accumulation of mtDNA in tumors. Experiments on cell culture models show that a high 
concentration of ROS is needed in order to exert an oxidative damage to the mtDNA most 
probably due to the protective role of the TFAM histone.127 The ROS induced mutational 
theory in cancer has been widely debated with some reports showing in vivo that high 
oxidative stress even in the presence of KOs of detoxifying genes does not induce a higher 
mutational rate.58,128. Since oxidative damage does not seem to offer a satisfactory 
explanation for the majority of the mutations seen, the next culprit would be POLG 
replication errors. This pattern is characterized by C>T and A>G substitutions. 129 
Mitochondrial genome replication process is hypothesized to have a bidirectional initiation. 
When reading mitochondrial variants, we use the Revised Cambridge Reference Sequence 
which uses the light (L) strand of the mtDNA. This strand contains the sense sequence for 
most of the mitochondrial genes. If a mutation, as for example a C>T change, is to occur on 
the L stand of the mtDNA it will be read as it is. But if the same change occurred on the H 
stand, this would appear as a G>A change in our gene and therefore in our report. This is 
precisely the situation we observe in this study, with more than half of all variants showing 
this mutational pattern. Since POLG is the enzyme replicating the mtDNA, we examined 
whether the patients from this study presented any somatic mutations in this gene and in 
others forming the mitochondrial DNA replication machinery and found only three patients. 
This led us to conclude that in the case of HCC, the mtDNA mutations are not caused by a 
dysfunctional replication due to mutations in the genes for replication machinery. 
Nevertheless, mutations in the replicative genes are not needed for the occurrence 
and accumulation of replication-related mtDNA mutations. These could be due to the 
increase mitochondrial biogenesis, thus the increase of POLG activity as it needs to keep the 
pace of the high tumoral proliferation rates. In such a situation even a wild-type replicaton 
machinery would allow the occurrence and accumulation of mtDNA mutations.130 Some 
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authors suggest that C>T POLG replication errors occur more frequently on the H strand131 
thus increasing the number of G>A events on the L strand.  
Another possible situation is that during mtDNA replication the displaced H strand is 
single stranded rendering it vulnerable to cytosine deamination.49,132 This creates a C>T 
substitution on the H strand which will appear as a G>A change on our reference L strand. 
Moreover, in this situation the H strand is also prone to adenine deamination leading to a 
T>C change.130 Indeed approximately 35% of our discovered variants are C>T and T>C 
alterations. In addition, there is also evidence for a different efficacy of the repair 
mechanisms between the H and the L strand.133–135 
Another known source of DNA variation is represented by technical error introduced 
during the prepararion steps of NGS. It has been shown that the C>T/G>A change has been 
shown to have the highest error rate during the steps of the technique, event most likely 
due to the spontaneous deamination of a methylated cytosine to uracil136. Nevertheless, in 
the absence of a confirmation with a secondary technique such as Sanger sequencing, the 
contribution of NGS technical errors cannot be excluded. 
 
Different pharmaceutical drugs as well as environmental toxins begin to be 
discovered as mitochondrial intoxicants.137 The most well-known mutation induced by 
environmental toxins is the aflatoxinB induced mutation in the TP53 gene. The liver is the 
main organ responsible for detoxification of the whole body. Frequent aggressions caused 
by chronic alcohol consumption, drug abuse as well as environmental factors can lead to 
liver damage and increased levels of ROS which could lead to a favorable environment for 
the acquisition of different mutations. Moreover, Chronic HBV and HCV infections have 
been found to disrupt the normal mitochondrial function. In our study we fail to find a 
difference in the distribution of the mtDNA mutations between the patients showing 
different backgrounds of HCC risks. Nevertheless, given the high frequency of comorbidities 
found in these patients that require the administration of different drugs which are mostly 
metabolized by the liver, one could also suppose that mtDNA mutations might arise as a 
consequence of the subsequent drug induced liver injury.  
It has been widely accepted that the tumoral microenvironment plays an important 
role in tumoral development. One of its components, the tumoral infiltrating immune cells 
have been shown to be of high relevance for prognosis in cancer as it can predict clinical 
outcome of patients and their response to therapy. In HCC, there a growing body of 
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research in the past years as the usage of immunotherapy with immune checkpoint 
inhibitors expands also for these tumors. Here we find that the burden of somatic 
pathogenic mitochondrial DNA mutations located in genes coding for CI and CIII subunits 
influences the percentage of intratumoral lymphocytic infiltration.  
We also see that patients with pathogenic mutations have a lower survival rate that 
those with non-pathogenic variants. Since immunohistochemical analysis is limited to the 
total lymphocyte infiltration, we could not asses the different subsets of these immune cells. 
Tumoral infiltrating lymphocytes have been shown to have bidirectional role in the 
development of HCC with a opposite impact of prognosis. For example, tumors showing a 
high density of the CD3+ antigen have a better outcome as evaluated by a longer disease 
free survival and overall survival138. The opposite situation in which tumors having a low 
density of CD3+ show a poor prognosis is also true.139,140 Since CD3 is a common antigen 
expressed on all T-lymphocytes, these results are in accordance with our findings. Further 
detailed research is required to investigate this aspect and characterize the subsets of 
lymphocytes. Missense pathogenic mutations in CI and CIII are thought to cause an increase 
in ROS production which could raise the intratumoral level of oxidative stress 95. Such a 
milieu has been shown to inactivate and reduce the survival of T cells ultimately leading to a 
diminished antitumoral activity. With T cell-based immunotherapy on the rise, 
understanding and counteracting the mechanisms which lead to induced T cell suppression 
and hyporesponsiveness is critical to ensure therapeutic success. 
An interesting observation is that of the infiltration pattern presented by tumors 
harboring mutation in CV subunits. Even though we could not perform any statistical 
analysis because only one tumor presented a benign CV variant, we can see that this tumor 
had an insignificant level of stromal component while the others bearing pathogenic 
mutations presented up to 20% of stromal component. This could be due to the fact that 
mutations in ATP synthase subunits would cause an energetic deficit141 which the tumor 
might compensate by attracting stromal cells such as cancer associated fibroblasts (CAFs) or 
tumor associated macrophages (TAMs) to aid their growth. This idea is supported also by 
the fact that we observed a negative selection of a CV germline pathogenic mutation. 
Another interesting observation following the same idea is that of mutations located in 
genes coding for transporter RNAs. Although failing to achieve statistical significance, 
tumors presenting pathogenic mutations in tRNA genes seem to have a higher stromal 
component as well as a higher level of immune infiltrate. This could be explained by the fact 
that tRNA mutations may cause an impairment in mitochondrial protein synthesis 
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consequently leading to a decrease in proteins constructing the OXPHOS chain and thus a 
decline in ATP production required for cellular function.142,89 This, again, would render 
cancer cells dependent on the microenvironment for their proliferation. For example, CAFs 
have been shown to transfer to tumoral cells various molecules such as non-coding RNAs, 
different metabolites amino acids and whole proteins through exosomes in various types of 
cancers,143–145 as well as in HCC.146,147 Moreover, metabolites originating from such vesicles 
have been shown to regulate mitochondrial OXPHOS and glycolysis in recipient tumoral 
cells.148 Furthermore, in breast cancer exosomes deriving from stromal cells have been 
shown to transfer mtDNA to tumoral cells, supporting OXPHOS and mediating the exit from 
chemotherapy induces dormancy.149 Exosomes deriving from tumor-associated 
macrophages have also been shown to transfer proteins to cancer cells and contribute to 
tumor aggressiveness and metastasis.145 
As far as the immune infiltration represented by monocytes and neutrophils, 
statistical analysis revealed no difference in infiltration rates between the tumors harboring 
pathogenic mutations and those without, although we can observe an overall general 
tendency for tumors with pathogenic variants to show a higher amount of these two 
components. 
Neutrophils have been known to play an important role in chronic inflammatory 
diseases as well as in cancer. Recent studies have shown that they play vital functions in the 
tumoral milieu although the precise nature in different cancers is still under discussion150. In 
general, tumor associated neutrophils are considered to have a pro-tumorigenic effect 
facilitating tumoral progression and to even aid in establishing the premetastatic niche.151 In 
liver cancer, neutrophils have been associated with a significant decrease in survival 
rates.152 
Similarly to neutrophils, high infiltration rates of monocytes into the tumor milieu 
are associated with poor clinical outcome in different cancers such as breast, lung and 
ovarian cancers,153–155 as well as in HCC.156,157 TAMs which can derive from monocytes, have 
been shown to modulate the tumor microenvironment and decrease therapeutic 
success.158,159 For example, tumors with CI deficiency have been shown to be capable of 
inducing angiogenesis by recruiting TAMs.160 
The impact of mtDNA mutations on clinical outcome and survival of cancer patients 
has been under debate by many authors.161–164 In this study survival analysis showed that in 
the TCGA-HCC cohort, mtDNA mutations can predict overall survival, as patients harboring 
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pathogenic mutations presented a lower survival rate than those without such variants. It is 
known that some mtDNA mutations induce mitochondrial dysfunction with consequent 
increase of ROS levels,165 and HCC tumors are characterized by high levels of endogenous 
ROS.166 This persistent oxidative stress could lead to DNA damage, activation of oncogenes 
ultimately causing cancer development. Moreover, ROS contribute to angiogenesis, 
activation of epithelial to mesenchymal transition and metastasis, all features found in 
HCC.167 Even though the mutational signature found in the cohort of HCC samples analyzed 
in this study, was not of ROS origin, the increased generation of ROS as a consequence of 
mtDNA mutations is likely to contribute to the aggressiveness by facilitating tumoral 
proliferation and invasion, thus explaining the poor prognosis of these patients. In spite of 
such a positive correlation found in this study, because of the relatively small sample size, 
larger studies are required to strengthen the value mtDNA mutations as a prognostic factor 
in HCC. 
The remarkable ability of the liver to regenerate after large hepatectomies in which 
more than half of the liver is removed has had researchers believe in the existence of a stem 
cell compartment in the liver.168 A stem cell has two main features: the capacity to self-
renewal and expand clonally. This has been shown by the fact that transplanted hepatocytes 
in a diseased liver have the capacity of expanding clonally. 169 Similar to the tracing of the 
origins and migration of human populations, cells can be traced back using mtDNA variants. 
Tracking differentiated cells to their stem cell progenitor has been shown has been shown in 
the case of colonic crypt cells which show the accumulation of mtDNA mutations 
particularly in CIV that originate from the stem cells laying in the base of the crypt.170 On the 
same note, one study reports the presence of cytochrome c oxidase deficient patches in 
normal livers171 similar to those we found in our study. The authors go further to report the 
presence of clonal mtDNA mutations in these nodules, further confirming the idea of that 
these cells originate from a common progenitor cell. Thus, one could think that a similar 
situation could be found also in our samples. Considering all the aforementioned 
arguments, the fact that we see a mixture of cells with low and high intensity signals for 
different mitochondrial complexes sustains the idea of a polyclonal origin of HCC tumors 







Hepatocellular carcinoma remains an aggressive tumor with a poor prognosis 
despite the medical advancements. Until present the treatment options available showing 
modest results combined with the advanced stage at diagnosis allows these tumors to 
remain a difficult and often incurable clinical challenge. 
This study has analyzed the occurrence of mtDNA mutations in the LIHC-TCGA cohort 
and found pathogenic mutations in 21% of patients. In such cases, it may be hypothesized 
that mtDNA mutations could cause mitochondrial dysfunction and contribute to 
hepatocarcinogenesis, by increasing the production of ROS and oxidative stress, thus fueling 
the tumor machinery.  
The search for a better therapy for liver cancer has proven to be a difficult challenge. 
The high heterogeneity of the tumor combined with the lack of established makers for 
therapeutic response have led to a great failure of many clinical trials. Thus, gaining further 
insight into the mechanisms which contribute to HCC development and exploring them in 
the context of therapy response represents a must in order to develop efficient therapeutic 
strategies. Here we found a correlation between mutations present in genes coding for CI 
subunits and the amount of stromal component and intratumoral infiltration of immune 
cells, factors which are known to support tumoral growth, invasion and metastasis. 
Moreover, we found a significant impact of mtDNA mutations on the overall survival, as the 
patients bearing tumors with pathogenic mutations showed a poorer survival. 
Currently there is a limited understanding of the potential impact of mitochondrial 
dysfunction in tumoral aggressiveness and clinical outcome of HCC. In this setting, ongoing 
research is needed in order to completely understand the impact of mitochondrial 
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LIHC_54 
LIHC_54_T Primary Tumor 100.00% 33.28 HV16 
LIHC_54_B Blood Derived Normal 100.00% 38.24 HV16 
LIHC_55 
LIHC_55_T Primary Tumor 100.00% 97.71 U5a1d2b 
LIHC_55_B Blood Derived Normal 100.00% 89.89 U5a1d2b 
LIHC_56 
LIHC_56_T Primary Tumor 99.90% 82.43 H13a1a1b 
LIHC_56_B Blood Derived Normal 100.00% 71.37 H13a1a1b 
LIHC_57 
LIHC_57_T Primary Tumor 100.00% 83.79 J1c2h 
LIHC_57_B Blood Derived Normal 99.80% 52.45 J1c2h 
LIHC_58 
LIHC_58_T Primary Tumor 99.90% 84.82 T1a1_152 
LIHC_58_B Blood Derived Normal 100.00% 97.22 T1a1_152 
LIHC_59 
LIHC_59_T Primary Tumor 100.00% 126.47 J1b1a1 
LIHC_59_NST Solid Tissue Normal 100.00% 425.63 J1b1a1 
LIHC_60 
LIHC_60_T Primary Tumor 99.90% 62.45 H7d3a 
LIHC_60_NST Solid Tissue Normal 100.00% 600.57 H7d3a 
LIHC_61 
LIHC_61_T Primary Tumor 100.00% 353.12 H1e1a 
LIHC_61_NST Solid Tissue Normal 100.00% 406.85 H1e1a 
LIHC_62 
LIHC_62_T Primary Tumor 100.00% 394.99 K1a4a1f 
LIHC_62_NST Solid Tissue Normal 100.00% 396.78 K1a4a1f 
LIHC_63 
LIHC_63_T Primary Tumor 100.00% 105.54 H6a1b3a 
LIHC_63_NST Solid Tissue Normal 100.00% 473.06 H6a1b3a 
LIHC_64 
LIHC_64_T Primary Tumor 100.00% 111.57 H2a5b2 




LIHC_65_T Primary Tumor 100.00% 204.46 T16223C 
LIHC_65_NST Solid Tissue Normal 100.00% 111.36 T16223C 
LIHC_66 
LIHC_66_T Primary Tumor 100.00% 35.56 K1c2 
LIHC_66_B Blood Derived Normal 99.80% 51.81 K1c2 
LIHC_67 
LIHC_67_T Primary Tumor 99.90% 55.32 N21_195 
LIHC_67_B Blood Derived Normal 100.00% 70.13 N21_195 
LIHC_68 
LIHC_68_T Primary Tumor 100.00% 67.73 J1b1a1a 
LIHC_68_B Blood Derived Normal 99.80% 42.07 J1b1a1a 
LIHC_69 
LIHC_69_T Primary Tumor 99.70% 125.89 I1b 
LIHC_69_NST Solid Tissue Normal 99.10% 79.26 I1b 
LIHC_70 
LIHC_70_T Primary Tumor 99.80% 47.63 U5b3b1 
LIHC_70_B Blood Derived Normal 99.40% 35.99 U5b3b1 
LIHC_71 
LIHC_71_T Primary Tumor 100.00% 120.27 D1c 
LIHC_71_B Blood Derived Normal 99.70% 60.67 D1c 
LIHC_72 
LIHC_72_T Primary Tumor 99.60% 61.61 H2a2b4 
LIHC_72_B Blood Derived Normal 99.70% 35.93 H2a2b4 
LIHC_73 
LIHC_73_T Primary Tumor 99.90% 97.83 A2k1a 
LIHC_73_B Blood Derived Normal 99.70% 51.96 A2k1a 
LIHC_74 
LIHC_74_T Primary Tumor 100.00% 122.89 T2e 
LIHC_74_B Blood Derived Normal 99.90% 41.63 T2e 
LIHC_75 
LIHC_75_T Primary Tumor 100.00% 49.28 V2a1 
LIHC_75_B Blood Derived Normal 99.10% 30.62 V2a1 
LIHC_76 
LIHC_76_T Primary Tumor 99.20% 41.78 R11b 
LIHC_76_B Blood Derived Normal 99.40% 42.36 R11b 
LIHC_77 
LIHC_77_T Primary Tumor 100.00% 81.07 M7c1a3a 
LIHC_77_B Blood Derived Normal 100.00% 142.09 M7c1a3a 
LIHC_78 LIHC_78_T Primary Tumor 100.00% 404.32 M10a1b 
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LIHC_78_B Blood Derived Normal 100.00% 112.73 M10a1b 
LIHC_79 
LIHC_79_T Primary Tumor 99.30% 39.98 D4a 
LIHC_79_B Blood Derived Normal 99.90% 44.53 D4a 
LIHC_80 
LIHC_80_T Primary Tumor 99.70% 46.93 K1c1a 
LIHC_80_B Blood Derived Normal 99.90% 36.51 K1c1a 
LIHC_81 
LIHC_81_T Primary Tumor 100.00% 199.89 L2b1a3 
LIHC_81_B Blood Derived Normal 99.90% 33.62 L2b1a3 
LIHC_82 
LIHC_82_T Primary Tumor 100.00% 82.15 H1b1g 
LIHC_82_B Blood Derived Normal 99.90% 45.94 H1b1g 
LIHC_83 
LIHC_83_T Primary Tumor 100.00% 83.5 H1c1_16093 
LIHC_83_B Blood Derived Normal 99.90% 40.6 H1c1_16093 
LIHC_84 
LIHC_84_T Primary Tumor 99.90% 50.64 H13a1a1 
LIHC_84_B Blood Derived Normal 100.00% 42.9 H13a1a1 
LIHC_85 
LIHC_85_T Primary Tumor 99.90% 86.54 U5b2b3a1a 
LIHC_85_B Blood Derived Normal 99.80% 45.42 U5b2b3a1a 
LIHC_86 
LIHC_86_T Primary Tumor 100.00% 91.01 H3g3 
LIHC_86_B Blood Derived Normal 99.90% 58.55 H3g3 
LIHC_87 
LIHC_87_T Primary Tumor 99.86% 67.15 C1b 
LIHC_87_B Blood Derived Normal 98.10% 32.34 C1b 
LIHC_88 
LIHC_88_T Primary Tumor 99.10% 34.91 C1b 
LIHC_88_B Blood Derived Normal 99.50% 39.7 C1b 
LIHC_89 
LIHC_89_T Primary Tumor 100.00% 77.34 B2 
LIHC_89_B Blood Derived Normal 100.00% 93.43 B2 
LIHC_90 
LIHC_90_T Primary Tumor 99.50% 42.74 D1 
LIHC_90_B Blood Derived Normal 99.80% 36.37 D1 
LIHC_91 
LIHC_91_T Primary Tumor 99.80% 44.55 A2 




LIHC_92_T Primary Tumor 100.00% 87.16 H1b2 
LIHC_92_B Blood Derived Normal 99.80% 41.19 H1b2 
LIHC_93 
LIHC_93_T Primary Tumor 99.20% 34.96 B4c1b2a 
LIHC_93_B Blood Derived Normal 99.90% 40.52 B4c1b2a 
LIHC_94 
LIHC_94_T Primary Tumor 100.00% 82.15 L3e3b1 
LIHC_94_B Blood Derived Normal 100.00% 100.01 L3e3b1 
LIHC_95 
LIHC_95_T Primary Tumor 100.00% 69.29 U5a1a2b 
LIHC_95_B Blood Derived Normal 99.90% 49.86 U5a1a2b 
LIHC_96 
LIHC_96_T Primary Tumor 99.80% 49.47 K1a4 
LIHC_96_B Blood Derived Normal 100.00% 63.55 K1a4 
LIHC_97 
LIHC_97_T Primary Tumor 100.00% 123.83 K1a4a1h 
LIHC_97_B Blood Derived Normal 99.90% 72.09 K1a4a1h 
LIHC_98 
LIHC_98_T Primary Tumor 100.00% 110.72 W1c 
LIHC_98_B Blood Derived Normal 99.30% 40.72 W1c 
LIHC_99 
LIHC_99_T Primary Tumor 99.80% 45.42 J1c3b 
LIHC_99_B Blood Derived Normal 99.50% 36.05 J1c3b 
LIHC_100 
LIHC_100_T Primary Tumor 99.70% 35.45 T2b3_151 
LIHC_100_B Blood Derived Normal 99.80% 40.41 T2b3_151 
LIHC_101 
LIHC_101_T Primary Tumor 100.00% 140.37 T2a1a 
LIHC_101_B Blood Derived Normal 99.90% 41.22 T2a1a 
LIHC_102 
LIHC_102_T Primary Tumor 99.60% 32.12 L2b1a3 
LIHC_102_B Blood Derived Normal 99.80% 42.23 L2b1a3 
LIHC_103 
LIHC_103_T Primary Tumor 99.90% 67.72 K1d 
LIHC_103_B Blood Derived Normal 99.90% 35.89 K1d 
LIHC_104 
LIHC_104_T Primary Tumor 100.00% 124.58 H5a1 
LIHC_104_B Blood Derived Normal 99.50% 34.65 H5a1 
T: tumor; B: blood; NST: normal solid tissue 
